Aim: To update the definitions of selected questions of the "QAA-25" (quantitative adherence assessment) scale and evaluate it according to the criteria of validity and measure of agreement.Materials and Methods. In a descriptive cross-sectional study including 200 patients with coronary heart disease, adherence was determined using traditional and alternative versions of selected questions of the QAA-25 scale, followed by assessment of construct validity, factor validity, and measure of agreement.Results. Alternative question versions did not significantly affect test results, with 81% of respondents in the outpatient sample and 69% in the inpatient sample rating them as "more acceptable." The QAA-25 scale has good construct and internal validity (α – 0.818, αst – 0.832), with moderate agreement (κ – 0.562) and demonstrates high reliability of internal validity – when scale items are consistently excluded, α values remain in the 0.801-0.839 range.Conclusion. The QAA-25 scale with modified question definitions should be used instead of the previous version of the scale. Good construct validity and factor validity, sufficient measure of agreement and specificity, high sensitivity and reliability of the QAA-25 scale allow to recommend it as a tool for assessing adherence to drug therapy, medical support, lifestyle modification and integral adherence to treatment in scientific and clinical practice.
2 April 2022 in International Journal of Psychiatry in Clinical Practice
Objective: To discuss the impact of depression on work and how depression-related sick leave duration could be a potential indicator and outcome for measuring functionality in depression. Methods: Our review was based on a literature search and expert opinion that emerged during a virtual meeting of European psychiatrists that was convened to discuss this topic. Results: Current evidence demonstrates that depression-related sick leave duration is influenced by multiple disease-, patient- and work-related factors, together with societal attitudes towards depression and socioeconomic conditions. A wide variety of pharmacological and non-pharmacological treatments and work-based interventions are effective in reducing depression-related sick leave duration and/or facilitating return to work. Recent real-world evidence showed that patients treated with antidepressant monotherapy appear to recover their working life faster than those receiving combination therapy. Although depression-related sick leave duration was found to correlate with severity of depressive symptoms, it cannot be used alone as a viable marker for disease severity. Conclusions: Given its multifactorial nature, depression-related sick leave duration is not on its own a viable outcome measure of depression severity but could be used as a secondary outcome alongside more formal severity measures and may also represent a useful measure of functionality in depression.
23 October 2023 in Neurology, Neuropsychiatry, Psychosomatics
Depression is one of the most common medical causes of disability and mortality in patients of all ages. Depressive disorders are common in the practice of physicians of a variety of specialties, including psychiatrists, neurologists, and physicians. This paper provides a summary review of the literature on modern ideas about the epidemiology, classification, and clinical picture of depression. Current approaches to the diagnosis and treatment of depressive disorders in neurological and psychiatric practice are discussed. Modern pharmacotherapeutic strategies for the treatment of depression in various patient populations are described in detail. Current clinical practice indicates the high importance of an interdisciplinary approach in the diagnosis and management of patients with depressive symptoms in Russia. The paper suggests organizational and educational strategies that can be recommended to improve the effectiveness of medical care for patients with depressive disorders.
26 February 2022 in Neurology, Neuropsychiatry, Psychosomatics
Sleep disturbances are common in patients with mental disorders. Sleep disturbances, in particular insomnia, are widespread in depression. Depressed patients have a lot of sleep complaints that are often confirmed by polysomnography. Most antidepressants impair sleep, so drugs that help to restore sleep are of particular value in clinical practice. Agomelatine (valdoxan) rapidly improves sleep in depressed patients by making it easier to fall asleep, increasing total sleep time, duration of rapid eye movement (REM), and slow-wave sleep (SWS), and improving functioning during the day.
17 November 2022 in Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics)
In Russia, the QAA-25 questionnaire is used to quantify the adherence to treatment of adult patients. The accumulated experience of its use made it possible to identify several cohorts of respondents, including adolescents, whose characteristics required special adaptation of the formulations of a number of questions.Purpose. The study aimed at modifying the questionnaire for quantitative assessment of treatment adherence QAA-25 for adolescents aged 15–17 years and evaluate it according to the criteria of validity and the measure of consent.Material and methods. In a descriptive one-stage study with the participation of 108 high school students at secondary schools in Omsk, the level of adherence to treatment was determined according to the QAA-25 scale, using traditional and alternative formulations of individual questions, with the formation of a modified scale and an assessment of its constructive and factor validity and a measure of consent.Results. Applying various options for testing alternative questions, the possibility and expediency of using them to assess the adherence to treatment of adolescents, including separately evaluated subsamples of male and female individuals, was shown. 94% of respondents rated alternative questions as “more acceptable,» 5% of respondents «did not notice significant differences,» and 1% of respondents rated them as «less acceptable.» The QAA-25 scale modified for adolescents demonstrated good structural and internal validity (α = 0.818, αst = 0.857), with high reliability (consistent exclusion of scale items preserves the validity of the questionnaire in the range of 0.793–0.858) and almost perfect agreement (κ = 1.000).Conclusion. The modified QAA-25 questionnaire is recommended to be used to assess the adherence to treatment and potential adherence to treatment of adolescents who have reached the age of 15 but have not reached the age of 18, both for research purposes and when making decisions related to the provision of medical care and the organization of preventive measures.
Клинико-динамические характеристики психозов, развившихся в результате употребления современных синтетических психоактивных веществ (ПАВ), имеют важные особенности, которые необходимо знать для точного установления диагноза и выбора терапевтической тактики. При этом динамика течения психозов, развившихся в результате приема современных синтетических ПАВ («спайсов», «солей» и «бутиратов»), остается недостаточно изученной. Цель данного исследования - изучить основные клинико-динамические характеристики психозов, развившихся на фоне употребления синтетических ПАВ. Методы исследования: клинико-психопатологический, лабораторный, психометрический, статистический. Обследовано 154 пациента с психозами, развившимися в результате употребления синтетических психоактивных веществ. Из них 53 пациента употребляли синтетические каннабиноиды или «спайсы», 54 - синтетические психостимуляторы (синтетические катиноны, меткатиноны, «соли») и 47 - синтетические агонисты рецепторов гамма-аминомасляной кислоты (ГАМК) - бутиролактон, 1,4-бутандиол или «бутираты». Психозы, развившиеся на фоне употребления современных синтетических ПАВ отличаются между собой по таким динамическим характеристикам как продолжительность, закономерности течения, исход, а также длительность последующей наркологической ремиссии в зависимости от вида психоактивного...